Moderate Hair Loss Research Articles

Effects of Withania somnifera root extract serum application on hair health in healthy adults: A prospective, double-blind, randomized, parallel, placebo-controlled study

BackgroundAlopecia is a dermatological condition affecting genders, negatively impacting their personality and quality of life (QoL). The current approved entities are limited, inconsistently effective, and associated with negative side effects. To alleviate this issue, ayurvedic herbs such as Ashwagandha have being explored. As a result, this study was designed to evaluate the efficacy and safety of Ashwagandha (root extract) topical formulation (serum) on hair health in healthy adults. MethodsIn this prospective, double-blind, randomized, placebo controlled, two arm, parallel, comparative study, the effects of topical Ashwagandha on the hair health was evaluated. Healthy adults between 18 and 45 years with mild to moderate hair loss were randomized to either Ashwagandha (topical) or Placebo (topical) treatment. The participants were assessed at Day-1 and Day-75 for change in efficacy parameters, which included 60 Seconds Hair Comb, Trichoscan analysis, Hair Pull test, Investigator's Global Assessment (IGA) and QoL using Hair-specific Skindex-29. ResultsIn the per protocol analysis of 61 participants, Ashwagandha group demonstrated significant reduction in hair shedding in the 60 Seconds Hair Comb test compared to Placebo at day 75. Similarly, Ashwagandha substantially enhanced hair density, growth, and thickness compared to the Placebo group (density = 7.3 vs. 2.8, P < 0.001; growth = 21.7 vs. 4.2, P < 0.001; thickness = 1.8 vs. 0.9, P < 0.001). In addition, Ashwagandha significantly improved QOL compared to placebo (Score = −17.3 vs. −6.1, P = 0.011). ConclusionThe study found that topical Ashwagandha (serum) improved hair growth and hair health indicators. Thus, it can be an effective and safer alternative for alopecia. Study registrationCTRI, Number CTRI/2022/11/047539, Registered on: 23/11/2022.

Self-Reported Hair Loss Following COVID-19: An Observational Study

Objective: COVID-19 has been significantly associated with both psychosocial stress and physiologic stress, both of which are known to trigger telogen effluvium. This study was performed to estimate the prevalence of hair loss among patients with COVID-19 and to determine the correlation of the severity of COVID-19 with the severity of hair loss. Methods: Data were collected through a self-administered electronic questionnaire that was distributed among social media platforms. Participants were invited to complete the survey using a convenience sampling technique. A multiple response dichotomies analysis and chi-square test of independence were used to analyze data. Results: Among 420 participants who reported a positive PCR result of SARS-CoV-2, 77.6% reported hair loss after COVID-19 development. Notably, the onset of hair loss was within 3 weeks of COVID-19 development in 29% of participants. Most of the participants reported that the duration of hair loss was up to 6 months, and hair regrowth was noticed within 1 year after COVID-19 development. Patients who were admitted to the hospital, who experienced respiratory difficulties, who had lost weight due to COVID-19, and who experienced symptoms for longer than 10 days were significantly more prone to experience severe hair loss following COVID-19 (P &lt; 0.001). Conclusion: This study demonstrated a high frequency of self-reported hair loss after the development of COVID-19. Interestingly, even patients with mild COVID-19 symptoms were significantly more prone to experience moderate hair loss. Unique to COVID-19 infection, the onset of hair loss following the development of COVID-19 was within 3 weeks in one-third of the participants.

A community-based study of hair care practices, scalp disorders and psychological effects on women in a Suburban town in Southwest Nigeria.

The scalp hairs on an average African is dry with low tensile strength and a tendency to break easily. This is mostly due to poor penetration of the natural oils on the scalp and the very curly hair texture. Various techniques developed to manage African hair are associated with certain hair and scalp disorders and are sources of distress. This was a cross-sectional survey to compare natural African hair and chemically processed (relaxed) hair to determine the effect of hair care and grooming practices on common scalp disorders and the psychological effect in Nigerian women. Questionnaires were administered to women at the market, churches and outreaches with many women in attendance to document the hair grooming practices, common scalp symptoms and psychological effects experienced. They were also examined for the presence of seborrhoeic dermatitis and traction alopecia. The study involved 452 women (62.17%) with relaxed hair and 275 women (37.83%) with natural (untreated) hair. Women with relaxed hair experienced significantly more flaking of the scalp (P = 0.046, x2 = 6.16), hair breakage (P = 0.023, x2 = 11.35) and hair loss (P = 0.020, x2 = 7.87) than those with natural hair. The most common psychological effects of hair scalp disorders in all participants were feeling of uneasiness 142 (19.5%), frustration 49 (6.7%), poor body image 40 (5.5%) and anger 38 (5.2%). Significantly more women with relaxed hair experienced moderate hair loss from traction than women with natural hair (P = 0.014, x2 = 8.52). Nigerian women experienced clinical and psychological distress consequent to their hair grooming practices. Individuals with relaxed hair had more physical symptoms, hair loss and psychological disturbances than those with natural hair.

34301 The relationship between the degree of scalp hair loss and health-related quality of life among patients with alopecia areata

Background: Previous research suggests that alopecia areata (AA) negatively impacts patients’ health-related quality of life (HRQL) including considerable psychosocial impacts. Purpose of the current study was to examine relationship between AA scalp hair loss and HRQL impacts. Methods: This cross-sectional, web-based survey included patients recruited through a patient foundation who self-reported a physician diagnosis of AA. Survey included questions on disease characteristics, patient burden and impact (assessed through Skindex-16 for AA and questions on work and sexual relationships), healthcare utilization, and treatment experience. Results: Patients with AA (N = 1327) completed the survey, mean age 39.7 years (SD = 12.3), 58.4% female. Patients were diagnosed on average 10.5 years ago (SD = 12.2). The degree of current hair loss included: 0% (2.6%), 1-20% (39.8%), 21-49% (26.2%), 50-94% (10.2%), and 95-100% (21.3%) of scalp hair missing. There was a non-linear relationship between HRQL and current patient-reported AA scalp hair loss. Patients with 1-94% of current scalp hair missing reported higher symptom, functioning, and emotional impacts due to AA than patients with 0% or 95-100% missing scalp hair (all P < .0001). Patients with moderate and large areas of hair loss reported greater impact on work (P < .0001) and sexual relationships (P < .001). Females reported higher impact on emotions due to AA (P = .014), while males reported higher impact in all other areas (P < .05). Conclusion: There is a nonlinear relationship between AA scalp hair loss and impacts on HRQL. Future research may help elucidate why those with the greatest amount of hair loss appear to cope better than those with moderate hair loss.

Morphological diagnosis and successful treatment of chorioptic mange in 2 South American coatis (Nasua nasua).

Two female South American coatis (Nasua nasua) kept in a zoo in Southern Germany presented with pruritus and moderate hair loss at the dorsal trunk, thigh areas and alongside the tail. Otherwise the animals showed no clinical signs. While the clinical general examination as well as cytology of dermatologic samples showed no pathologic changes, Chorioptes sp. mites could be identified in a superficial skin scraping. Two consecutive topical applications of a selamectin/sarolaner spot-on formulation 4 weeks apart lead to a complete resolution. No side effects were observed.

Association of type 2 diabetes with central centrifugal cicatricial alopecia: A follow-up study

To the Editor: Central centrifugal cicatricial alopecia (CCCA) is a scarring hair loss that starts in the central scalp and expands into the periphery during the chronicity of the disease.1 Recent data indicate a complex disease phenotype consisting of environmental and genetic components.2 However, few studies have directly shown evidence of medical risk factors for the disease. Population survey studies have shown a high prevalence of central hair loss in Black women with type 2 diabetes (DM2).

Abstract CT159: First-in-human dose escalation of AlphaMedixTM for targeted alpha-emitter therapy of neuroendocrine tumors

Abstract Introduction: Peptide Receptor Radioligand Therapy (PRRT) has been shown to be an effective treatment for patients with metastatic somatostatin receptor (SSTR) positive neuroendocrine tumors (NETs), however interest in developing alpha-emitter based therapies remains high. We present the initial safety and preliminary efficacy of this first-in-human (FIH) study of AlphaMedix™ (212Pb-DOTAMTATE), a novel somatostatin analog for Targeted Alpha-emitter Therapy (TAT), in patients with SSTR expressing NETs (FDA IND 135150). Methods: Thirteen adult subjects, 6 men and 7 women, median age 68 (range 27-75), with biopsy-proven unresectable or metastatic SSTR (+) NETs from different primary sites (small bowel, pancreas, and lung) with at least one measurable lesion were treated with a Single, weight-based, Ascending Dose (SAD) of AlphaMedix™. Dose escalation was conducted according to a classic 3+3 design. Once a partial response was observed in the SAD-3 cohort, the Multiple Ascending Dosing (MAD) began at the same dose level (3 cycles dosed every 8-weeks). Subjects who had previously received PRRT were excluded. All patients received amino acid renal protection prior to AlphaMedixTM administration. Response to treatment was measured per RECIST 1.1 and the effect on the quality of life was measured with the EORTC-QLQ-C30 QOL questionnaire. Two SAD cohorts (SAD1 and SAD2) received 30.7 and 40.0 µCi/kg respectively. MAD3 received 52.0 µCi/kg per cycle and MAD4, began dosing at 67.6 µCi/ kg for a total dose ranging from 14.7 to 16.8 mCi, across 3 cycles. Results: All 3 subjects in MAD 4 who received 67.6 µCi/ kg for 3 cycles showed partial response with 73%, 71%, and 33% decrease in size of the index lesions respectively. 68Ga DOTATATE PET/CT revealed almost a complete response in 2 subjects and a partial response in the third. No clinically significant investigational drug-related hematological and renal toxicity was noted. The most common adverse events noted were diarrhea 2/13(23%), nausea 4/13(30%), fatigue 4/13(30%), hyperglycemia 7/13(53%). Moderate hair loss was seen in 2/13 (15%) patients. Quality of life parameters suggest significant improvement in pain, energy, and shortness of breath in the majority of subjects. Conclusion: Dramatic decreases in tumor burden and a positive impact on quality of life were seen in all of the subjects who received three cycles of AlphaMedixTM at the highest dose tested. In addition, AlphaMedixTM was extremely well tolerated with only mild adverse events, most of which were attributable to the AA solution used for renal protection. This FIH study of AlphaMedixTM illustrates that PRRT with 212Pb is feasible, well-tolerated, and provides substantial reduction in tumor burden to patients with unresectable, metastatic SSTR expressing NETs Citation Format: Izabela Tworowska, Ebrahim S. Delpassand, Julien Torgue, Farah Shanoon, Jason Hurt, Rodolfo Nunez. First-in-human dose escalation of AlphaMedixTM for targeted alpha-emitter therapy of neuroendocrine tumors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT159.

Association of type 2 diabetes with central-scalp hair loss in a large cohort study of African American women.

BackgroundHair loss on the central scalp commonly occurs among African American (AA) women and can pose substantial psychosocial burdens. The causes of hair loss remain obscure, although type 2 diabetes has been hypothesized to increase the risk of hair loss. The objective of the present study was to prospectively estimate the association between type 2 diabetes and severe central hair loss in AA women.MethodsThe Black Women’s Health Study has collected data on medical and lifestyle factors, including diagnosis of type 2 diabetes, biennially since 1995 from AA women across the United States. The present analysis was based on responses from 5389 women to an online hair loss questionnaire in 2015. Respondents indicated severity of central hair loss on a validated six-item photographic scale; the highest levels, levels 3 to 5, were designated as severe. We used Cox proportional hazards models to estimate multivariable hazard ratios and 95% confidence intervals (CIs) for type 2 diabetes in relation to severe central hair loss.ResultsDuring the follow-up period, 850 cases of severe hair loss occurred. The multivariable hazard ratio for severe hair loss associated with diabetes was 1.68 (95% CI, 1.38-2.06) overall, and 2.05 (95% CI, 1.48-2.85) for diabetes duration of ≥ 10 years.ConclusionType 2 diabetes was associated with an increased risk of severe central scalp hair loss in AA women. Patients with type 2 diabetes should be followed closely for central scalp hair loss so that appropriate treatment can be offered.

The Correlation between Diabetes Status and Hair Loss among Aged Women in Alor Setar Area

The aim of this study was to identify the diabetes among aged women in Alor Setar area and to compare association between diabetes and current hair loss condition. Across sectional study was conducted to study the prevalence between diabetes and hair loss among aged women around Alor Setar area. Primarily data was collected using interviewer-administered questionnare consisting of socio-demographic questions for part A-the aged of the women, employment status and diabetes status. Stress level for part B and the hair loss scale for part C. As a part of population based on cross sectional study, the hair status of 112 aged women range 50–60 years was assessed by answering questionare, 56 from them suffered with diabetes and another 56 of them non-diabetes. The aged women with yes diabetes status have a highest prevalence of excessive hair loss which is 93.6% compare to non-diabetes aged women with excessive hair loss is 6.4%. Based on the table aged women who are non-diabetes have high prevalence hair loss in moderate hair loss which is 69.7% compared to women with diabetes status and experiencing hair loss which is 30.3%. Besides, the prevalence of non-diabetic aged women with normal hair loss is high which is 93.8% compared to diabetic aged women who experiencing normal hair loss is 6.3%. The result from this table showed that the P value is 0.000. The P value is less than 0.01. So, the null hypothesis for fifth objective rejected. Thus, there is significant relationship between diabetes status and hair loss. The result supports the hypothesis that aged women with diabetic experiencing hair loss.

Central hair loss in African American women: Incidence and potential risk factors

Central hair loss in African American women: Incidence and potential risk factors

Medical and Environmental Risk Factors for the Development of Central Centrifugal Cicatricial Alopecia

To investigate medical and environmental risk factors for central centrifugal cicatricial alopecia (CCCA), the most common type of scarring alopecia in African American women. A population study involving a quantitative cross-sectional survey of risk factors for CCCA. Survey results are then correlated with a clinical evaluation for CCCA using a standardized, previously published central scalp alopecia photographic scale. Two African American churches and a health fair for African American women in Cleveland, Ohio. A total of 326 African American women who participated in the hair study. Prevalence of CCCA in the general African American population and risk factors associated with CCCA. Of the 326 responders, 28% received a grade of 2 or higher using a standardized, previously published central scalp alopecia photographic scale, a score consistent with clinically evident central hair loss. Advanced central hair loss with clinical signs of scarring (grade ≥ 3) was seen in 59% of these respondents and was interpreted as clinically consistent with CCCA. Diabetes mellitus type 2 was significantly higher in those with CCCA (P = . 01), as were bacterial scalp infections (P = .045) and hair styles associated with traction (eg, from braids and weaves) (P = .02). Our survey results suggest that there is a high prevalence of central hair loss among African American women. Hair styles causing traction as well as inflammation in the form of bacterial infection may be contributing to the development of CCCA. The increase in diabetes mellitus type 2 among those with CCCA is in line with the recent theory that cicatricial alopecia may be a manifestation of metabolic dysregulation.

Hedgehog antagonist GDC‐0449 is effective in the treatment of advanced basal cell carcinoma

To demonstrate the efficacy of the hedgehog pathway inhibitor GDC-0449 in the treatment of advanced basal cell carcinoma. Case series. Three patients treated in a referral center for locally advanced basal cell carcinoma, one with metastases, were referred for treatment in a GDC-0449 phase I clinical trial. The treatment was once per day continuous therapy with oral GDC-0449. Two patients showed complete clinical and radiologic resolution of disease, whereas one patient had significant reduction in tumor burden with radiologic evidence of slowly progressive local disease. Side effects were taste changes, mild to moderate hair loss, and muscle cramps in one patient. GDC-0449 showed significant inhibitory activity in the treatment of advanced basal cell carcinoma.

Central hair loss in African American women: Incidence and potential risk factors

Although central scalp hair loss is a common problem in African American women, data on etiology or incidence are limited. We sought to determine the frequency of various patterns and degree of central scalp hair loss in African American women and to correlate this with information on hair care practices, family history of hair loss, and medical history. Five hundred twenty-nine subjects at six different workshops held at four different sites in the central and/or southeast United States participated in this study. The subjects' patterns and degree of central scalp hair loss were independently assessed by both subject and investigator using a standardized photographic scale. Subjects also completed a detailed questionnaire and had standardized photographs taken. Statistical analysis was performed evaluating answers to the questionnaire relative to pattern of central hair loss. Extensive central scalp hair loss was seen in 5.6% of subjects. There was no obvious association of extensive hair loss with relaxer or hot comb use, history of seborrheic dermatitis or reaction to a hair care product, bacterial infection, or male pattern hair loss in fathers of subjects; however, there was an association with a history of tinea capitis. There was no scalp biopsy correlation with clinical pattern of hair loss and further information on specifics of hair care practices is needed. This central scalp photographic scale and questionnaire provide a valid template by which to further explore potential etiologic factors and relationships to central scalp hair loss in African American women.

Central scalp alopecia photographic scale in AfricanAmerican women

Central centrifugal cicatricial alopecia (CCCA) is a common but poorly understood cause of hair loss in African American women. A photographic scale was developed that captures the pattern and severity of the central hair loss seen with CCCA in order to help identify this problem in the general community and to potentially correlate clinical data with hair loss. The utility and reproducibility of this photographic scale was determined in a group of 150 African American women gathered for a health and beauty day who were evaluated by both four investigators experienced in the diagnosis of hair disorders and by the subjects themselves.

Alopecia due to psychotropic medications.

To review the literature and describe the incidence and nature of psychotropic drug-related alopecia to assist clinicians in their therapeutic decisions when this adverse event occurs. A MEDLINE search (December 1966-March 1998), using each drug name and the keywords alopecia or hair loss, was conducted. A database from the Clarke Institute of Psychiatry in Toronto was also searched. Additional English-language articles were identified through the bibliography of the reviewed literature. Certain pharmaceutical companies were also consulted. All published case reports and review articles were considered for study evaluation. When possible, details regarding psychotropic drug therapy, development of alopecia, and clinical outcomes were collected for each case. Hair loss from the scalp, eyebrows, and pubic area was identified as a possible, yet uncommon, adverse effect of most psychotropic medications. There are few effective management options for alopecia; however, resolution was achieved on discontinuation of the offending drug in almost all of the cases reported. Alopecia was perceived to be an undesirable effect by most patients, often resulting in poor compliance and hence therapeutic failures. Due to the self-limiting nature of mild to moderate hair loss with psychotropic medications, clinicians should consider continuing therapy if there is a good clinical response and the patient agrees with this decision. If severe alopecia occurs, it is recommended to discontinue the medication and pursue therapy with another agent. This is to ensure positive therapeutic outcomes and improved patient compliance.

Calcitriol ointment in the treatment of facial, hairline and retroauricular chronic plaque psoriasis

Psoriatic lesions on the face can be particularly distressing for patients as they are clearly visible and difficult to hide or disguise. The treatment of such lesions is also problematic as many of the most widely used agents, such as topical corticosterolds, cannot be used routinely on facial skin. Local and systemic safety, tolerability and efficacy of twice daily application of 3 μg/g calcitriol ointment in the treatment of moderate to severe facial, hairline and retroauricular chronic plaque psoriasis were assessed in an open study in ten patients. The duration of treatment was 6 weeks. The treatment was well tolerated, and no serious adverse events occurred. One patient had a transient mild skin irritation reaction and transient moderate hair loss, and another patient had transient mild seborrhoeic dermatitis near the right nose fold. In the baseline/endpoint comparison no statistically significant changes were observed in the mean values of serum total calcium, serum albumin-adjusted total calcium,...

Immunological treatment of alopecia areata including the use of diphencyprone

Immunomodulation is a characteristic shared by all modes of treatment which have a beneficial effect on hair regrowth in alopecia areata (AA). In AA with moderate hair loss, the chances of spontaneous remission are favourable and an expectative policy is indicated. Only in severe cases of AA is treatment justified. Topical immunotherapy with diphencyprone (or alternatively squaric acid dibutylester) is the treatment of choice, combining the highest rate of effectiveness with acceptable adverse effects. Despite considerable drawbacks, PUVA therapy can be considered as an alternative. Systemic administration of corticosteroids or cyclosporin A produces unacceptable side-effects and their topical application is ineffective. Intradermal injections of corticosteroids, however, can be very successful in AA of the eyebrows. me therapeutic effect of inosiplex and dapsone lacks confirmation in appropriately controlled studies.

Weak Direct Current Accelerates Split-Thickness Graft Healing on Tangentially Excised Second-Degree Burns

We have examined the effects of direct current (DC) conducted through silver-nylon dressings on the healing time and morphologic maturation of split-thickness grafts placed on tangentially excised deep partial-thickness burn wounds. Male guinea pigs (n = 120) were used as the experimental hosts. The DC-treated animals required 2 days for complete revascularization of their grafts; control animals required 7 days (p less than 0.01). The DC-treated animals had increased epithelial proliferation at the graft-wound interface as compared with controls (p less than 0.01). Grafts from DC-treated animals were firmly adherent within 4 days, whereas graft adherence in controls was weak before 7 days after grafting. At 3 months after grafting, control animal grafts had mild contraction with moderate hair loss and thick subepidermal fibrosis; the grafts in DC-treated animals expanded with the growth of the animals and had abundant hair growth and significantly reduced dermal fibrosis (p less than 0.01).

Hepatic adrenergic receptors in the genetically diabetic C57 BL/KsJ (db/db) mouse

1. 1. At 30 weeks of age, homozygote diabetic C57 BL KsJ (db/db) mice were grossly obese, lethargic and displayed moderate hair loss relative to heterozygote control C 57 BL KsJ (db/+) mice. 2. 2. In diabetic mice, compared to control, the total body weights, liver weight: body weight ratios, and blood glucose levels were increased 2.3 fold, 20% and 3.1 fold, respectively. 3. 3. Analysis of plasma membranes isolated from control and diabetic mouse liver established that comparable purity levels were achieved since relative specific activities of the plasma membrane markers 5′-nucleotidase and γ-glutamyltranspeptidase were similar: 10.2 and 11.4 fold with respect to 5′-nucleotidase in control and diabetic states respectively; and 8.0 and 8.3 fold with respect to γ-glutamyltranspeptidase in control and diabetic states respectively. 4. 4. A select effect of diabetes on γ-glutamyltranspepetidase, however, was observed. The activity of this enzyme was found to be reduced 16% in diabetic liver compared to control liver. 5. 5. Assessment of [ 3H]prazosin and [ 3H]dihydrolalprenolol binding to mouse liver plasma membranes indicated that although there was no difference in β-adrenergic receptor binding in control and diabetic states, α 1-adrenergic receptor binding was found to be reduced 43% in diabetic mouse liver plasma membranes. 6. 6. Scatchard analyses of kinetic studies indicate that the reduction is a reflection of decreases in α 1-adrenergic receptor numbers with no change in α 1 receptor affinity in the diabetic state: since for diabetic and control liver plasma membranes, K d values were 3.40 ± 0.02 nM and 3.40 ± 0.01 nM respectively; and B max were 650.12 ± 16.44 fmol mg −1 and 380.76 ± 12.92 fmol mg −1, respectively.

Multistage tattoo removal using carbon dioxide laser

The carbon dioxide laser is an effective and convenient method for tattoo removal, but when this is undertaken in a single stage as previously recommended by Bailin et al., and Beacon (1980), severe scarring may follow. Multistage removal with the instrument in perfect focus was tried, therefore, and found to be advantageous, with excellent results in 25 of 28 patients. Hypertrophic scars may occur and are treated by vaporization to a point just below the level of the surrounding epidermis with the subsequent daily use of clobetasol ointment until the wound has healed. The number of laser treatments required is given in the table. Table TABLE. Number of treatments No. of treatments No. of patients 1 5 2 7 3 11 ≥4 5 The quality of the final result was assessed by (a) skin texture and scarring; (b) presence of normal hair growth where appropriate; and (c) alteration in skin pigmentation. The quality of the scar was flat and impalpable in 25 of the 28 patients. Hair growth was unchanged in six of seven hirsute patients with moderate hair loss in one. Twenty-six patients healed with the skin normally or slightly depigmented, but there was moderate post-inflammatory pigmentation in two. Neither the site or size of the tattoo nor the age or sex of the patient seemed to be important. Relatively poor results were obtained in three patients whose common characteristic was that their tattoos had been professionally applied and that a large number of treatments (six to eight) had been required to remove all the pigment suggesting that this had been deeply placed in the dermis. However, good results were obtained in three other professional tattoos removed in three or more stages.